Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director | June 09, 2026 | June 11, 2026 |
| Epizyme, Inc.EPZM · Entity 12703 | See Remarks | August 16, 2021 | August 18, 2021 |
| Verastem, Inc.VSTM · Entity 5242 | Chief Operating Officer | April 01, 2025 | April 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.98 · Expires 2036-06-09 | Direct | 17,901 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 17,901 · Balance 17,901 F1: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Epizyme, Inc.
Report date August 16, 2021 · Filed August 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 111,313 |
Reported balance
After 2021-08-16 transaction · row 1
1 source rowRow 1 · 2021-08-16 · Grant · Acquired 28,125 · Balance 111,313 F1: Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2031-08-15 | Direct | 134,178 |
Reported balance
After 2021-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-16 · Grant · Acquired 134,178 · Balance 134,178 F2: This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022.
F2: This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.
Verastem, Inc.
Report date April 01, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2025-04-01 transaction · row 1
1 source rowRow 1 · 2025-04-01 · Grant · Acquired 50,000 · Balance 50,000 F1: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's inducement award program. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the shares subject to the award on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's inducement award program. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the shares subject to the award on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 17,901 | $0.00 Strike: $31.98 | $0.00 |
DisclosureSEC source: 0001193125-26-267666 · ownership.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:21 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 44,700 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0000950170-25-082365 · ownership.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 44,700 shares Expires 2035-06-04 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:30 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031706 · tm2511477-1_4seq1.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's inducement award program. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the shares subject to the award on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 13, 2024 23:14 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 44,700 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0000950170-24-073235 · ownership.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 44,700 shares Expires 2034-06-05 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:20 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 3,051 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0000950170-24-001876 · ownership.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,051 Underlying: Common Stock · 3,051 shares Expires 2034-01-02 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:56 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,170 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000950170-23-051615 · ownership.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,170 Underlying: Common Stock · 2,170 shares Expires 2033-10-02 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:53 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,743 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0000950170-23-031702 · ownership.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,743 Underlying: Common Stock · 1,743 shares Expires 2033-07-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:41 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 36,700 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0000899243-23-014890 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,700 Underlying: Common Stock · 36,700 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:15 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000899243-23-010391 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,900 shares Expires 2033-04-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:31 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,792 | $7.19 Strike: $11.07 | $12,876.24 |
DisclosureSEC source: 0000899243-23-000619 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,792 Underlying: Common Stock · 1,792 shares Expires 2033-01-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:35 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,419 | $9.08 Strike: $14.33 | $12,878.84 |
DisclosureSEC source: 0000899243-22-032672 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,419 Underlying: Common Stock · 1,419 shares Expires 2032-10-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 17:51 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,194 | $5.87 Strike: $9.39 | $12,880.10 |
DisclosureSEC source: 0000899243-22-024929 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,194 Underlying: Common Stock · 2,194 shares Expires 2032-07-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:09 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0000899243-22-021645 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2032-06-07 F1 · derivative.exercise_date: This annual stock option award was made on the date of the 2022 Annual Meeting of Stockholders pursuant to the company's Non-Employee Director Compensation Program and shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,650 | $4.86 Strike: $7.92 | $12,879.00 |
DisclosureSEC source: 0000899243-22-013702 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650 Underlying: Common Stock · 2,650 shares Expires 2032-04-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:24 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,256 | $5.15 Strike: $8.70 | $11,625.17 |
DisclosureSEC source: 0000899243-22-000691 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,256 Underlying: Common Stock · 2,256 shares Expires 2032-01-03 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:11 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,463 | $5.03 Strike: $8.54 | $12,393.08 |
DisclosureSEC source: 0000899243-21-039303 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,463 Underlying: Common Stock · 2,463 shares Expires 2031-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 12:02 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 134,178 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000899243-21-033402 · doc4.xml · derivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,178 Underlying: Common Stock · 134,178 shares Expires 2031-08-15 F2 · derivative.exercise_date: This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 12:02 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033402 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,313 F1 · shares: Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:08 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,225 | $4.78 Strike: $8.02 | $10,625.27 |
DisclosureSEC source: 0000899243-21-027628 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225 Underlying: Common Stock · 2,225 shares Expires 2031-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:06 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,068 | $5.66 Strike: $9.08 | $11,695.99 |
DisclosureSEC source: 0000899243-21-014967 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,068 Underlying: Common Stock · 2,068 shares Expires 2031-04-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 23:00 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000899243-21-011694 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a three year period. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 894 | $11.21 | $10,021.74 |
DisclosureSEC source: 0000899243-21-005033 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,188 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on February 3, 2020. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 02:05 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 134,178 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0000899243-21-004508 · doc4.xml · derivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,178 Underlying: Common Stock · 134,178 shares Expires 2031-01-31 F2 · derivative.exercise_date: This option was granted on February 1, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 25% vesting on February 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 02:05 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004508 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,082 F1 · shares: Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 1, 2022. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 01:42 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 2,872 | $11.41 | $32,769.52 |
DisclosureSEC source: 0000899243-21-003533 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,957 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on January 24, 2019. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person acquired (i) 708 shares of Common Stock under the Issuer's 2013 Employee Stock Purchase Plan (the "2013 ESPP") on August 31, 2018 and (ii) 614 shares of Common Stock under the 2013 ESPP on February 28, 2019 that were not previously reported on Form 4. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:48 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,641 | $0.00 Strike: $7.62 | $0.00 |
DisclosureSEC source: 0000899243-21-000793 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,641 Underlying: Common Stock · 1,641 shares Expires 2031-01-04 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 21:30 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 9,247 | $1.35 Strike: $2.26 | $12,500.09 |
DisclosureSEC source: 0001209191-20-053276 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,247 Underlying: Common Stock · 9,247 shares Expires 2030-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:27 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 35,280 | $0.31 Strike: $0.47 | $11,000.30 |
DisclosureSEC source: 0001209191-20-041017 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,280 Underlying: Common Stock · 35,280 shares Expires 2030-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 12:54 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 2,728 | $16.15 | $44,057.20 |
DisclosureSEC source: 0000899243-20-017900 · doc4.xml · nonDerivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,507 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 12:54 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017900 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,235 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,651 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · derivative · entry 9 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,787 Underlying: Common Stock · 68,651 shares Expires 2026-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,289 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · derivative · entry 8 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,577 Underlying: Common Stock · 2,289 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option was granted on February 8, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 109,866 shares of Common Stock, with 25% vesting on February 8, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,063 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · derivative · entry 7 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,557 Underlying: Common Stock · 41,063 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option was granted on January 24, 2019 pursuant to the Company's 2013 Stock Incentive Plan with respect to 151,620 shares of Common Stock, with 25% vesting on January 24, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 68,651 | $21.65 | $1,486,294.15 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · nonDerivative · entry 6 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,798 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 per share to $22.00 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 68,651 | $9.58 | $657,676.58 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · nonDerivative · entry 5 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 2,289 | $22.00 | $50,358.00 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · nonDerivative · entry 4 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,798 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 2,289 | $12.45 | $28,498.05 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · nonDerivative · entry 3 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 41,063 | $20.50 | $841,791.50 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · nonDerivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,798 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 23:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 41,063 | $9.12 | $374,494.56 |
DisclosureSEC source: 0000899243-20-017434 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:25 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 14,331 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-035929 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 Underlying: Common Stock · 14,331 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 49,887 | $0.22 Strike: $0.35 | $11,000.08 |
DisclosureSEC source: 0001209191-20-023946 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,887 Underlying: Common Stock · 49,887 shares Expires 2030-04-06 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 01:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,243 | $15.28 | $18,993.04 |
DisclosureSEC source: 0000899243-20-009606 · doc4.xml · nonDerivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,798 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 24, 2020 Filed Mar 27, 2020 01:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 1,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009606 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,041 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| March 24, 2020 Filed Jun 30, 2020 10:10 UTC Amendment | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017858 · doc4a.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,235 F1 · shares: The Form 4 originally filed on March 26, 2020 inadvertently reported an incorrect amount of shares of common stock issued to the reporting person upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan. F1 · price: The Form 4 originally filed on March 26, 2020 inadvertently reported an incorrect amount of shares of common stock issued to the reporting person upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:03 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 56,213 | $0.00 Strike: $21.39 | $0.00 |
DisclosureSEC source: 0000899243-20-003372 · doc4.xml · derivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,213 Underlying: Common Stock · 56,213 shares Expires 2030-02-02 F2 · derivative.exercise_date: This option was granted on February 3, 2020 pursuant to the Company's 2013 Stock Incentive Plan with respect to 56,213 shares of Common Stock, with 25% vesting on February 3, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:03 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock | 11,688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003372 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,478 F1 · shares: Consists of shares of Common Stock issuable under 11,688 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 3, 2021. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 02:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | Tax withholdingCommon Stock, par value $0.0001 | 2,395 | $22.40 | $53,648.00 |
DisclosureSEC source: 0000899243-20-002114 · doc4.xml · nonDerivative · entry 3 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,790 Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 02:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,847 | $24.64 | $45,510.08 |
DisclosureSEC source: 0000899243-20-002114 · doc4.xml · nonDerivative · entry 2 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,185 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| January 23, 2020 Filed Jan 28, 2020 02:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002114 · doc4.xml · nonDerivative · entry 1 Ros Matthew · CIK 0001673802 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,032 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:45 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 24,274 | $0.45 Strike: $0.72 | $11,000.98 |
DisclosureSEC source: 0001209191-20-001885 · doc4.xml · derivative · entry 1 Ros Matthew · CIK 0001673802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,274 Underlying: Common Stock · 24,274 shares Expires 2030-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.